Renal Artery Stents For Zfen: Vbx Vs. Atrium Icast
Peter V. Cooke, BA1, Vikram Vasan, BA1, Justin M. George, MD2, Halbert Bai, MPH1, Christopher Faries, BA1, Ajit Rao, MD2, Michael L. Marin, MD2, Peter L. Faries, MD1, James McKinsey, MD2, Rami O. Tadros, MD1
1Icahn School of Medicine at Mount Sinai, New York, NY, 2Division of Vascular Surgery, Mount Sinai Hospital, New York, NY.
Objective: Viabahn balloon-expandable (VBX) and Atrium iCast stents are commonly deployed in the renal arteries for fenestrated endovascular aneurysm repair (FEVAR). We compared outcomes of VBX vs. Atrium iCast renal stents with the Cook ZFEN device. Methods: A single center’s prospectively maintained aortic database was analyzed for all patients undergoing FEVAR from April 2016 to June 2021. Patients were stratified into two cohorts: VBX vs. iCast renal stent. Outcomes included primary patency, stent-related reintervention, postoperative change in renal function, endoleak, and 30-day mortality. Results: Among 64 patients, 85 VBX stents and 31 iCast stents were placed. Demographics and comorbidities were similar between cohorts. Years of follow-up differed significantly (3.0vs.1.1,p<0.001), as VBX stents are a more contemporary device.Five (10.9%) VBX and two (11.8%) iCast stents lost patency (p=1.000). Indication for reintervention did not differ between cohorts (p=0.333) (Table). Eight (12.1%) VBX and two (11.1%) iCast patients experienced a three-stage or greater increase in chronic kidney disease staging (p=0.638). There was no significant difference in endoleak rates (p=0.785). There were not significantly higher odds of endoleak on univariate (p=0.953) or multivariate analysis (p=0.543).). Six (13.0%) VBX and three (16.7%) iCast patients required reintervention for endoleaks. One (2.2%) VBX patient and zero (0%) iCast patients experienced 30-day postoperative mortality (p=0.590). Conclusion: Both VBX and iCast stents offer excellent primary patency and low endoleak rates when used in renal arteries for FEVAR. 
Back to 2022 ePosters